<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230490</url>
  </required_header>
  <id_info>
    <org_study_id>RNA200103-202</org_study_id>
    <nct_id>NCT00230490</nct_id>
  </id_info>
  <brief_title>Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201</brief_title>
  <official_title>Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <brief_summary>
    <textblock>
      Compare the long-term safety of pradefovir to adefovir dipivoxyl
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Compare the long-term safety of pradefovir to adefovir dipivoxyl

        -  Monitor development of resistance

        -  Evaluate virologic and biochemical response
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse findings from nonclinical carcinogenicity studies.
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Safety: Clinical examinations of laboratory tests</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>- Efficacy: Change in viral load over time</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Efficacy: Proportion of patients with undetectable viral load</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pradefovir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adefovir dipivoxyl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed 48 weeks of treatment in study RNA200103-201

        Exclusion Criteria:

          -  Patients who were determined to be treatment failures in study RNA200103-201

          -  Patients who experienced a serious adverse event judged to be related to study drug in
             study RNA200103-201

          -  Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive
             determinations in study RNA200103-201
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph T. Doyle</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals International, Inc.</affiliation>
  </overall_official>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B, Chronic</keyword>
  <keyword>Hepatitis B Virus</keyword>
  <keyword>Pradefovir Mesylate</keyword>
  <keyword>Adefovir Dipivoxyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

